Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of March 2025, with a specific announcement date of March 21, 2025. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS).
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to a capital transaction:
- Share Repurchase: Haleon completed an off-market purchase of 44,155,844 ordinary shares from Pfizer Inc.
- Transaction Value: The aggregate purchase price was approximately £170 million.
- Share Status: The repurchased shares have been cancelled.
Material Changes
The material change reported is the reduction in the company's share capital following the cancellation of the repurchased shares. As of March 21, 2025:
- Total Ordinary Shares Issued: 9,039,570,075
- Treasury Shares: 4,080,205
- Shares with Voting Rights: 9,035,489,870
This updated figure serves as the denominator for shareholders calculating notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, specific risk factors, or contingencies beyond the completion of the share repurchase. The document focuses solely on the capital structure update.
Key Facts for Investor Verification
- Verify the updated total number of voting shares (9,035,489,870) for compliance with disclosure thresholds.
- Confirm the cancellation of the 44,155,844 shares repurchased from Pfizer Inc.
- Note that this filing does not include quarterly or annual financial results; investors should refer to the most recent Form 20-F or earnings release for operational metrics.